Parry Bio

Parry Bio-Sciences is an innovative biotechnology company dedicated to the discovery and development of next-generation small molecule drugs through Targeted Protein Degradation (TPD). Utilizing its proprietary platform, the company designs PROTACs and molecular glues that selectively degrade disease-causing proteins, particularly those considered undruggable by traditional inhibitors. Parry Bio-Sciences focuses primarily on oncology and inflammatory disorders, aiming to overcome resistance mechanisms in current therapies. The company is headquartered in India and maintains a robust R&D infrastructure to support its internal pipeline and potential collaborations. By integrating advanced computational tools with deep biological insights, Parry Bio-Sciences is positioning itself as a leader in the TPD space within the emerging biotech landscape.